Latest:
Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes
Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Anita Shaffer
Associate Director of Editorial, Print
Latest:
Neoadjuvant Therapy Helps Shape Changing Landscape of Early-Stage NSCLC
The treatment of patients with early-stage non–small cell lung cancer is rapidly evolving across the spectrum of care, particularly in the neoadjuvant setting, where evidence in favor of systemic chemoimmunotherapy regimens is growing.
Ann H. Klopp, MD, PhD
Latest:
Dr. Klopp on the Future of Chemoradiation in Endometrial Cancer
Ann H. Klopp, MD, PhD, an associate professor of radiation oncology at The University of Texas MD Anderson Cancer Center, discusses the future of chemotherapy in combination with radiation for the treatment of patients with endometrial cancer.
Ann Janssens, MD
Latest:
Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients
A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.
Ann LaCasce, MD
Latest:
Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo
Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.
Ann-Lii Cheng, MD
Latest:
Dr. Cheng on the Need For Biomarkers in HCC
Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.
Ann-Lii Cheng, MD, PhD
Latest:
Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials
Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.
Ann McMahon Wicker, PharmD, BCPS
Latest:
Clinical and Economic Considerations for the Use of Erythropoiesis-Stimulating Agents
Erythropoiesis-stimulating agents (ESAs) are genetically engineered forms of erythropoietin that stimulate erythropoiesis through direct or indirect action on the erythropoietin receptor producing an increase
Ann Ridgon, MSN, RN, OCN
Latest:
UVA Screening Program Seeks to Get Ahead of Colorectal Cancer
Approximately 1 of every 20 Americans will be diagnosed with colorectal cancer at some point in their life, and the American Cancer Society estimates that most colorectal cancer deaths can be prevented by screening.
Ann S. LaCasce, MD, MMSc
Ann S. LaCasce, MD, MMSc, is an associate professor of medicine and a lymphoma specialist at Dana-Farber Cancer Institute in Boston, Massachusetts and Director of the Dana-Farber/Mass General Brigham Fellowship in Hematology/Oncology.
Latest:
Career Development and Mentorship in Medicine
Ann LaCasce, MD, MMSc; and Judith Trotman, MBChB, FRACP, discuss career development and mentorship in medicine.
Ann W. Silk, MD
Latest:
The Search for Immune-Specific Biomarkers Is in Full Swing
An improved understanding of how the immune system recognizes and eradicates cancer cells, along with advances in drugs that effectively promote antitumor immune responses, is revolutionizing the field of cancer therapy.